ALK-Positive
Treating Metastatic Non-Small Cell Lung Cancer With Driver Mutations
The Fellow on CallThe Fellow on Call | September 22, 2023
What's the best approach for treating metastatic non-small cell lung cancers that possess certain mutations?
Listen Now
First-Line Lorlatinib Improves Survival and Metastasis in Advanced ALK-Positive Lung Cancer
Rebecca AraujoNon-Small Cell Lung Cancer | September 21, 2023
Early treatment with the anaplastic lymphoma kinase (ALK)-inhibitor lorlatinib reduced cancer progression and death in ...
Read More
FDA Approves New Treatment for ALK-Positive Metastatic NSCLC
Kerri FitzgeraldNon-Small Cell Lung Cancer | September 19, 2023
The U.S. Food and Drug Administration approved lorlatinib for patients with ALK-positive metastatic non-small cell ...
Read More
Advertisement
Advertisement
Latest News

Lenvatinib Plus Tislelizumab Offers Antitumor Activity for First-line Treatment of uHCC

May 4, 2024

FDA Approves High-Concentration Cyltezo for Treatment of Chronic Inflammatory Diseases

May 3, 2024

FDA Approves Therapy for Metastatic Cervical Cancer

May 3, 2024

  • 630 Madison Ave.

    Manalapan, NJ 07726

    • About

    About Us

    Editorial Policy

    Advertising

    Connect

    eNewsletters

    Contribute

    Contact Us

    Our Network

    MashupMD

    Blood Cancers Today

    Cancer Nursing Today

    GU Oncology Now

    Urban Health Today

    © 2024 Mashup Media, LLC. All rights reserved.

    Terms of Use | Privacy Policy